Leveraging Genome Editing to Study Childhood Leukemia

The central question of our lab is to understand how a normal blood stem cell can become cancerous. In leukemia, the initiating genetic mutations occur as early as during fetal development. Our team applies cutting-edge CRISPR/Cas9 genome editing approaches in human primary blood stem cells to model the pre-leukemic and leukemic phases of acute myeloid and acute lymphoblastic leukemia in vivo. The goal is to uncover insights into the genetic, cellular and developmental mechanisms of leukemia, with a particular focus on childhood leukemia, and identify therapeutic vulnerabilities of the disease.

We are located on the 24th floor of the Annenberg Research Building at the Icahn School of Medicine at Mount Sinai.